"investigational"@en . . . . "biricodar"@en . . . . . "Humans and other mammals"@en . . . "Biricodar dicitrate"@en . . . . . . . "174254-13-8"@en . . . "The pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1)."@en . . . . . . "Administered intravenously, biricodar dicitrate is to be used in combination with cancer chemotherapy agents."@en . . "# Gandhi L, Harding MW, Neubauer M, Langer CJ, Moore M, Ross HJ, Johnson BE, Lynch TJ: A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer. 2007 Mar 1;109(5):924-32. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17285598 # Mullin S, Mani N, Grossman TH: Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853). Antimicrob Agents Chemother. 2004 Nov;48(11):4171-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15504837"@en . . . "Vertex’s research shows that biricodar dicitrate can enhance the accumulation of chemotherapy agents in tumor cells by blocking the drug pumps P-gp and MRP, and that it is capable of restoring the sensitivity of tumors to treatment with chemotherapeutic agents."@en . . . . .